IQ-AI Ltd operates as an investment company. The principal activity of the group is the provision of convenient, cost-effective, and clinical treatments to patients in the field of medical imaging diagnostics, based on proven technologies. Its geographical segment includes Jersey and the United States of America and reportable segments are holding company expenses and medical software. The company derives a majority of revenue from the United States of America. It also supplies medical technology solutions and has a strong neuroimaging product portfolio.
Quote | IQ-AI Limited (OTCMKTS:IQAIF)
Last: | $0.02 |
---|---|
Change Percent: | 0.0% |
Open: | $0.02 |
Close: | $0.02 |
High: | $0.02 |
Low: | $0.02 |
Volume: | 19,952 |
Last Trade Date Time: | 05/22/2024 03:00:00 am |
News | IQ-AI Limited (OTCMKTS:IQAIF)
(NewsDirect) Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblasto...
--News Direct-- Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring gliob...
Message Board Posts | IQ-AI Limited (OTCMKTS:IQAIF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
(NewsDirect) Dr Jennifer Connelly, MD, the Principal Investigator (PI) of the IQ-AI Limited sponsored phase one clinical trial that is being conducted at the Medical College of Wisconsin, joined Proactive's Stephen Gunnion with a positive update from its treatment for recurring glioblasto...
--News Direct-- Dr Jennifer Connelly, the Principal Investigator (PI) of the IQ-AI Limited sponsored Phase I Clinical Trial that is being conducted at the Medical College of Wisconsin, joins Proactive's Natalie Stoberman to discuss the latest updates from its treatment for recurring gliob...
MILWAUKEE, WI / ACCESSWIRE / July 13, 2023 / Imaging Biometrics, LLC (IB) , a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI)(OTCQB:IQAIF) , today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of p...